| Typicality: | 0.434 |
| Saliency: | 0.053 |
| upon determination of disease progression | 8 | temporal |
| subcutaneously | 4 | manner |
| week → be administered until → 3 weeks | 4 |
| negative | neutral | positive |
| 0.109 | 0.869 | 0.022 |
| Raw frequency | 4 |
| Normalized frequency | 0.053 |
| Modifier score | 1.000 |
| Perplexity | 422.005 |